Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell 2Subcutaneous panniculitis-like T-cell lymphoma 1Mycosis Fungoides 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Immunoblastic Lymphadenopathy 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

pembrolizumab 86Cyclophosphamide 58Carboplatin 57Specimen Handling 55fludarabine 46Nivolumab 44Magnetic Resonance Spectroscopy 44Gemcitabine 41Biopsy 40Bevacizumab 36Dexamethasone 32venetoclax 31Paclitaxel 29Cisplatin 29Pemetrexed 28Injections 28Docetaxel 26atezolizumab 22Ipilimumab 22Capecitabine 22Temozolomide 21Rituximab 20Oxaliplatin 20Cetuximab 20Azacitidine 20Lenalidomide 19Fulvestrant 19abemaciclib 18Fluorouracil 17Vincristine 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × 10-propargyl-10-deazaaminopterin × 90 days × Clear all
NCT03598998 2026-05-26

Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

City of Hope Medical Center

Phase 1/2 Active not recruiting
13 enrolled 12 charts
DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Follicular, Mycosis Fungoides, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

NCT07225985 2026-05-11

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Fred Hutchinson Cancer Center

Phase 1/2 Recruiting
50 enrolled
Lymphoid

Lymphoma, T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡